| Ankylosing spondylitis
Hyrimoz vs Simponi
Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.Deep comparison between: Hyrimoz vs Simponi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSimponi has a higher rate of injection site reactions vs Hyrimoz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Simponi but not Hyrimoz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrimoz
Simponi
At A Glance
SC injection
Every other week
TNF-alpha antagonist
SC injection
Every 4 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis Vulgaris
- Hidradenitis
- Uveitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile rheumatoid arthritis Weight-based SC dosing every other week for patients >=2 years: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg); same dosing applies to pediatric uveitis patients.
Crohn Disease Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; pediatric patients >=6 years receive weight-based loading doses followed by 20 or 40 mg every other week.
Ulcerative Colitis Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis Vulgaris, Uveitis 80 mg initial SC dose, then 40 mg every other week starting one week after initial dose.
Hidradenitis Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week SC starting Day 29; adolescents >=12 years receive weight-based dosing (80 mg Day 1 for 30 to <60 kg, or 160 mg Day 1 for >=60 kg).
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once a month.
Ulcerative Colitis (adults and pediatric patients >=40 kg) 200 mg SC at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks.
Ulcerative Colitis (pediatric patients >=15 kg to <40 kg) 100 mg SC at Week 0, 50 mg at Week 2, then 50 mg every 4 weeks.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, abdominal pain, back pain, urinary tract infection, flu syndrome, accidental injury, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Most common (>=1%) Upper respiratory tract infection, viral infections, bronchitis, superficial fungal infections, sinusitis, injection site reaction, alanine aminotransferase increased, aspartate aminotransferase increased, hypertension, dizziness, paresthesia, constipation
Serious Serious infections, malignancies, congestive heart failure, demyelinating disorders, hepatitis B reactivation, autoimmunity, hematologic cytopenias, hypersensitivity reactions
Postmarketing Serious systemic hypersensitivity reactions, sarcoidosis, melanoma, Merkel cell carcinoma, interstitial lung disease, skin exfoliation, lichenoid reactions, rash, bullous skin reactions
Pharmacology
TNF-alpha antagonist; adalimumab-adaz is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Golimumab is a human IgG1 monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing its binding to receptors and inhibiting the biological activity of TNF-alpha in inflammatory diseases.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrimoz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Simponi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Hyrimoz
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Simponi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (7/8) · Qty limit (7/8)
Humana
Hyrimoz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Simponi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrimoz.
No savings programs available for Simponi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrimozView full Hyrimoz profile
SimponiView full Simponi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.